[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613337":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":36,"locations":42,"responsibleParty":58,"collaborators":10,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"City of Hope Medical Center","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"HCC (Discovery, Small RNA-seq)",null,"Patient diagnosed with hepatocellular carcinoma, including cases with HBV-, HCV-, and NBNC-related etiologies. Blood or other biospecimens will be collected for multi-omics profiling",[13,14],"Diagnostic Test: Small RNA sequence","Diagnostic Test: Rt-qPCR",{"label":16,"type":10,"description":17,"interventionNames":18},"Chronic Liver Disease (CLD) cohort","Patients with chronic liver disease, including liver cirrhosis and chronic hepatitis, without evidence of hepatocellular carcinoma.\n\nBlood or other biospecimens will be collected for multi-omics profiling.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Healthy Controls","Healthy individuals without known liver disease or malignancy who will provide blood or other biospecimens as normal controls for biomarker evaluation.",[13,14],[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"DIAGNOSTIC_TEST","Small RNA sequence","Comprehensive small RNA sequencing of serum or plasma-derived cf-tsRNAs to identify candidate biomarkers distinguishing HCC from NDC.",[16,9,20],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"Rt-qPCR","Construction of integrated cf- tsmiRNAs diagnostic classifier using machine learning",[16,9,20],{"type":25,"name":30,"description":34,"armGroupLabels":35,"otherNames":10},"PCR-based validation of the tsRNA panel",[16,9,20],[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Goel Ajay, PhD","CONTACT","626-218-3452","ajgoel@coh.org",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Duarte","California","91016","United States",{"type":50,"coordinates":51},"Point",[52,53],-117.97729,34.13945,{"lat":53,"lon":52},[56],{"name":57,"role":39,"phone":40,"phoneExt":10,"email":41},"Ajay Goel, PhD",{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100613337",false,"NCT07265271","Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)","CENTINEL","Inclusion Criteria:\n\n* Adults aged 18 to 100 years.\n* A histologically confirmed diagnosis of hepatocellular carcinoma.\n* A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma.\n* Healthy volunteers without known liver disease or malignancy.\n* Received standard diagnostic and staging procedures as per local guidelines\n* Availability of blood or other biospecimens.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Lack of or inability to provide informed consent\n* History of other active malignancies within the past 5 years\n* Previous liver transplantation\n* Severe systemic infection or inflammatory disease at the time of enrollment\n* Inadequate sample quality or quantity",true,"ALL","18 Years",{"count":70,"type":71},600,"ESTIMATED","OBSERVATIONAL","Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited.\n\nThis study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.",[75],"Hepatocellular Carcinoma (HCC)",[77,78,79,80,81],"HCC","Liver cancer","tsRNA","Liquid Biopsy","Early Detection","2026-06-30",{"date":84,"type":85},"2026-07-01","ACTUAL",{"date":87,"type":85},"2025-01-15",{"date":89,"type":71},"2028-06-18",{"name":5,"class":6},1]